Bloomberg Technology

Scribe Bets on a New Era of Gene Editing

Dr. Jennifer Doudna won the Nobel Prize for pioneering gene-editing technology CRISPR. Today, Scribe Therapeutics, the company she co-founded, just raised $128.7 million in its IPO for a much bigger ambition: using CRISPR to prevent heart disease. Scribe Therapeutics co-founder and Scientific Advisor Jennifer Doudna joins Ed Ludlow on “Bloomberg Tech” from the Nasdaq. ——–…

Published

1 day ago

on

Dr. Jennifer Doudna won the Nobel Prize for pioneering gene-editing technology CRISPR. Today, Scribe Therapeutics, the company she co-founded, just raised $128.7 million in its IPO for a much bigger ambition: using CRISPR to prevent heart disease. Scribe Therapeutics co-founder and Scientific Advisor Jennifer Doudna joins Ed Ludlow on “Bloomberg Tech” from the Nasdaq.
——–
Like this video? Subscribe to Bloomberg Technology on YouTube:

 
Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
Follow Caroline Hyde on X here:
 
Listen to the daily Bloomberg Technology podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Related Topics:

4 Comments

  1. @emmanouilafendakis2239

    July 25, 2026 at 1:06 am

    Hope the IPO goes well , crispr needs to progress and become mainstream !

    Reply

  2. @babarfahim6859

    July 25, 2026 at 5:38 am

    gene therapies should be banned. not a place to play in for nerds.

    Reply

  3. @hardheadjarhead

    July 25, 2026 at 6:19 am

    This didn’t tell me a thing as to how this works and what impacts are hoped for. Bad interview.

    Reply

  4. @skeletonghostcomedy4331

    July 25, 2026 at 2:41 pm

    What about TIGR?

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version